Direct Health Care Costs Associated With a Multicomponent COPD Exacerbation Intervention

REFERENCES

1. 1.↵
   Public Health Agency of Canada. Life and breath: respiratory disease in Canada (2007). Available at: https://www.canada.ca/en/public-health/services/reports-publications/2007/life-breath-respiratory-disease-canada-2007.html. Accessed June 27, 2023.
2. 2.↵
   1. Benady S

   . The human and economic burden of COPD: a leading cause of hospital admission in Canada. Ottawa, Ontario: Canadian Thoracic Society; 2010.
3. 3.↵
   1. Gershon A,
   2. Warner L,
   3. Cascagnette P,
   4. Victor J,
   5. To T

   . Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011;378(9795):991-996.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   The editors. Beyond the lungs-a new view of COPD. Lancet 2007;370(9589):713.

   OpenUrlPubMed
5. 5.↵
   1. O’Donnell D,
   2. Aaron S,
   3. Bourbeau J,
   4. Hernandez P,
   5. Marciniuk D,
   6. Balter M,
   7. et al

   . Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14 Suppl B(Suppl B):5B-32B.

   OpenUrlPubMedWeb of Science
6. 6.↵
   1. Rose L,
   2. Istanboulian L,
   3. Carriere L,
   4. Thomas A,
   5. Lee HB,
   6. Rezaie S,
   7. et al

   . Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC-COPD+): a randomized controlled trial. Eur Respir J 2018;51(1):1701567.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Lenferink A,
   2. van der Palen J,
   3. van der Valk P,
   4. Cafarella P,
   5. van Veen A,
   6. Quinn S,
   7. et al

   . Exacerbation action plans for patients with COPD and comorbidities: a randomized controlled trial. Eur Respir J 2019;54(5):1802134.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Lenferink A,
   2. Brusse-Keizer M,
   3. van der Valk PD,
   4. Frith PA,
   5. Zwerink M,
   6. Monninkhof EM,
   7. et al

   . Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;8(8):CD011682.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Effing TW,
   2. Vercoulen JH,
   3. Bourbeau J,
   4. Trappenburg J,
   5. Lenferink A,
   6. Cafarella P,
   7. et al

   . Definition of a COPD self-management intervention: International Expert Group consensus. Eur Respir J 2016;48(1):46-54.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Wodchis W,
    2. Bushmeneva K,
    3. Nicitovic M,
    4. McKillop I

    . Guidelines on person-level costing using administrative databases in Ontario. Working Paper Series Vol 1. 2013. Health System Performance Research Network. Available at: https://tspace.library.utoronto.ca/bitstream/1807/87373/1/Wodchis%20et%20al_2013_Guidelines%20on%20Person-Level%20Costing.pdf. Accessed June 27, 2023.
11. 11.↵
    1. Bai Y,
    2. Santos G,
    3. Wodchis W

    . Cost of public health services for Ontario residents injured as a result of a motor vehicle accident. Applied health research question series. 2016. Health System Performance Research Network. Available at: https://hspn.ca/wp-content/uploads/2019/09/AHRQ-Cost-of-Public-Health-Services-for-Ontario-Residents-Injured-as-a-Result-of-a-Motor-Vehicle-Accident.pdf. Accessed June 27, 2023.
12. 12.↵
    1. Austin PC,
    2. van Walraven C,
    3. Wodchis WP,
    4. Newman A,
    5. Anderson GM

    . Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care 2011;49(10):932-939.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Stephenson A,
    2. Hux J,
    3. Tullis E,
    4. Austin PC,
    5. Corey M,
    6. Ray J

    . Socioeconomic status and risk of hospitalization among individuals with cystic fibrosis in Ontario, Canada. Pediatr Pulmonol 2011;46(4):376-384.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Bourbeau J,
    2. Granados D,
    3. Roze S,
    4. Durand-Zaleski I,
    5. Casan P,
    6. Köhler D,
    7. et al

    . Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program. Int J Chron Obstruct Pulmon Dis 2019;14:645-657.

    OpenUrl
15. 15.↵
    1. Kessler R,
    2. Casan-Clara P,
    3. Koehler D,
    4. Tognella S,
    5. Viejo J,
    6. Dal Negro R,
    7. et al

    . COMET: a multicomponent home-based disease management program versus routine care in severe COPD. Eur Respir J 2018;51(1):1701612.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Patel J,
    2. Coutinho A,
    3. Lunacsek O,
    4. Dalal A

    . COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis 2018;13:2301-2311.

    OpenUrlPubMed
17. 17.↵
    1. Shah C,
    2. Reed R,
    3. Wastila L,
    4. Onukwugha E,
    5. Gopalakrishnan M,
    6. Zafari Z

    . Direct medical costs of COPD in the USA: an analysis of the medical expenditure panel survey 2017–2018. Appl Health Econ Health Policy 2023;21(6):915-924.

    OpenUrl
18. 18.↵
    1. Chen S,
    2. Kuhn M,
    3. Prettner K,
    4. Yu F,
    5. Yang T,
    6. Bärnighausen T,
    7. et al

    . The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. Lancet Glob Health 2023;11(8):e1183-e1193.

    OpenUrl
19. 19.↵
    GBD 2019 Chewing Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Public Health 2021;6(7):e482-e499.

    OpenUrl